$CIBearishMed

Piper Sandler Issues Pessimistic Forecast for Cigna Group (NYSE:CI) Stock Price

Piper Sandler cut its Cigna Group (CI) target price to $346 from $370 and kept an “overweight” rating, implying 26.47% upside from the prior close, according to MarketScreener. Other firms cited include UBS ($400 buy), Sanford C. Bernstein ($371 outperform), and Leerink ($297 market perform). Cigna last reported Q1 EPS of $7.79 vs $7.60 consensus and revenue of $68.52B.

7/10
6/10
Med
Bearish
today/next-session analyst-target reaction
moderately bearish (target cut) but partially offset by other analysts’ higher targets

Sell-side valuation reset for CI via a lowered target, with mixed corroboration from other analysts’ targets.

Piper Sandler cut its Cigna price target to $346 from $370 while keeping an “overweight” rating, signaling a more cautious valuation view.

Near-term pressure possible as the most prominent change cited is a target reduction, though other firms’ higher targets may cushion the move.

Background

The piece is an analyst-note roundup focused on Piper Sandler’s lowered CI target, alongside other sell-side target changes and a recap of CI’s latest earnings and FY 2026 EPS guidance.

Why it matters

A lowered target can drive short-term sentiment and options positioning, but the presence of multiple raised targets and recent earnings/guidance support can reduce follow-through selling.

Market relevance

CI’s valuation narrative is adjusted downward by one major broker, but the broader sell-side mix and recent earnings beat keep the signal less decisive.

Market effects

Signals health-insurance valuation debate rather than a sector-wide shock; may influence peers’ multiple expectations.

Primarily US-focused given CI’s NYSE listing; limited spillover beyond US managed-care sentiment.

Low; insurer-specific analyst note with no stated international catalyst.

Alternative perspectives

Despite the target cut, Piper Sandler maintains “overweight,” and several other analysts raised targets, suggesting the downgrade is not a fundamental thesis break.

The article also notes CI’s recent earnings beat and FY 2026 EPS guidance near consensus; traders may weigh those fundamentals more than a single target change.

Key entities

  • Cigna Group

    Subject of the article; Piper Sandler lowered its price target and other analysts issued differing target updates.

  • Piper Sandler

    Issued the pessimistic target revision for CI while retaining an “overweight” rating.

  • David Cordani

    CEO disclosed a large stock sale under a Rule 10b5-1 plan (Form 4 context in the article).

Related articles

$MCHPHighAI 9/10

Stocks Jump on US-Iran Peace Optimism

US stocks rose on optimism about US-Iran peace and supportive earnings. Bloomberg Intelligence said 83% of 475 S&P 500 Q1 reporters beat estimates; Q1 earnings are projected +12% y/y (ex-tech about +3%). S&P gains were led by chip/AI and airlines as WTI fell ~3%. Rates: 10-year yield fell ~7.5 bp to 4.483%; ECB swaps price a 91% chance of a +25 bp hike.

$CIMed

This Cigna Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday

Several Wall Street analysts have downgraded their ratings for four major companies. Deutsche Bank downgraded Cigna Group (CI) from Buy to Hold, Morgan Stanley downgraded Newell Brands Inc (NWL) from Equal-Weight to Underweight, Wolfe Research downgraded Crown Castle Inc (CCI) from Outperform to Peer Perform, and Seaport Global downgraded Dominion Energy Inc (D) from Buy to Neutral. These downgrades reflect changing outlooks on these stocks by top financial analysts.

$CIMed

Watch Cigna's president speak at BofA 2026 health conference

The Cigna Group announced that its President and COO, Brian Evanko, will present at the BofA Securities 2026 Health Care Conference on May 13, 2026, at approximately 12:20 p.m. ET. A live webcast of the presentation will be available on the company's investor relations website, and investors are advised to log in 15 minutes early to download any necessary audio software. The announcement follows strong Q1 2026 financial results and a raised outlook for adjusted income from operations.

$CIMed

Is It Time To Reassess Cigna (CI) After A 13.7% One Year Share Price Decline

Cigna Group (CI) shares have declined by 13.7% over the past year, prompting a reassessment of its valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is currently undervalued by 68.5% with an intrinsic value of $896.95 per share compared to its recent price of $282.90. Additionally, its P/E ratio of 11.90x is significantly lower than the industry average, also indicating potential undervaluation.